Price:
Rs. 22,000.00
Sample Type: Tissue
Fasting Not Required
Notes:N8194
Frequently Asked Questions (FAQ's):
What does the NextGen PulmoCore 12 Gene Panel (SP263) at Metropolis Healthcare include?
It includes NGS-based analysis of 12 lung cancer–related genes along with PD-L1 SP263 immunohistochemistry.
How does Metropolis Healthcare conduct this lung cancer gene panel?
Metropolis Healthcare uses high-depth sequencing for mutation detection and validated SP263 staining for PD-L1 scoring.
Who should consider taking this test at Metropolis Healthcare?
Patients diagnosed with or suspected of lung cancer who need evaluation for targeted or immunotherapy options should take this test.
Is fasting needed for this test at Metropolis Healthcare?
No fasting is required; tumor tissue and/or blood samples are used as per clinical guidance.
How long do results take at Metropolis Healthcare?
Results are typically available within 2–3 weeks due to extensive genomic and IHC evaluation.
Can this panel at Metropolis Healthcare help identify suitable targeted therapies?
Yes, the gene insights help guide targeted treatments, while PD-L1 SP263 scoring supports immunotherapy decisions.
How accurate is the PD-L1 SP263 analysis at Metropolis Healthcare?
Metropolis Healthcare uses validated protocols ensuring reliable and clinically meaningful PD-L1 scoring.
Does this panel assist with personalized treatment planning at Metropolis Healthcare?
Yes, the combination of genetic profiling and PD-L1 evaluation enables customized therapy selection for lung cancer patients.